European guidelines for quality assurance in colorectal cancer screening and diagnosis. First Edition – Organisation

Malila, Nea; Senore, Carlo; Armaroli, Paola

doi:10.1055/s-0032-1309783

Cited by 27 publications

(53 citation statements)

References 110 publications

(157 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the risks may be slight, they add up in the large number of people exposed to screening. Effective quality assurance ensures that the balance between the collective risk and the achieved benefit remains acceptable.Experience gained from piloting and implementing numerous cancer screening programmes in the EU confirms the well-known observation that overall screening outcome depends on the level of performance at each step in the process of screening [3,[13][14][15][16][41][42][43]; see also [44]. To maximize the benefit and minimize the risk of CRC screening, quality must be optimal throughout the process, and that includes the identification and personal invitation of the target population, the performance of the screening test and, if necessary, the diagnostic work-up of screen-detected lesions, and treatment, surveillance and aftercare [2,3].…”

mentioning

confidence: 59%

“…Each article covers one of the 10 chapters of the guidelines [3,[16][17][18][19][20][21][22][23][24], the annex of the chapter dealing with quality assurance in pathology [25], the section on principles of evidence assessment and methods for reaching recommendations [28], or the executive summary [26]. The results section of each chapter article begins with a list of key recommendations with a dual grading showing the strength of each recommendation and the supporting evidence.…”

Section: Author Manuscript Author Manuscriptmentioning

confidence: 99%

“…Comprehensive European quality assurance guidelines for breast and cervical cancer screening have been developed by experts and published by the EU [14,15]. The new European guidelines for quality assurance in colorectal cancer screening and diagnosis [3,[16][17][18][19][20][21][22][23][24][25][26][27]] make similar principles, standards and recommendations available to healthcare professionals, scientists, decision-makers and other stakeholders seeking to establish or improve CRC screening programmes.The content of the evidence-based multidisciplinary guidelines is presented in 13 articles in a recent Supplement to Endoscopy. Each article covers one of the 10 chapters of the guidelines [3,[16][17][18][19][20][21][22][23][24], the annex of the chapter dealing with quality assurance in pathology [25], the section on principles of evidence assessment and methods for reaching recommendations [28], or the executive summary [26].…”

mentioning

confidence: 99%

“…The new European guidelines for quality assurance in colorectal cancer screening and diagnosis [3,[16][17][18][19][20][21][22][23][24][25][26][27]] make similar principles, standards and recommendations available to healthcare professionals, scientists, decision-makers and other stakeholders seeking to establish or improve CRC screening programmes.…”

mentioning

confidence: 99%

“…Personal invitation aims to give each eligible person an equal chance of benefiting from screening and thereby reduce health inequalities. As with evidence-based screening for breast or cervical cancer, the population-based approach to programme implementation is also recommended for CRC screening because it provides an organizational framework conducive to effective management and continuous improvement of the screening process, such as through linkage with population and cancer registries for optimization of invitation to screening and for evaluation of screening performance and impact [3,[13][14][15][16][17]. Nationwide implementation of population-based screening programmes makes services performing to high standards available to the entire population eligible to attend screening.…”

mentioning

confidence: 99%

See 4 more Smart Citations

European guidelines for quality assurance in colorectal cancer screening and diagnosis: Overview and introduction to the full Supplement publication

Karsa¹,

Patnick²,

Segnan³

et al. 2012

Endoscopy

249

187

View full text Add to dashboard Cite

Population-based screening for early detection and treatment of colorectal cancer (CRC) and precursor lesions, using evidence-based methods, can be effective in populations with a significant burden of the disease provided the services are of high quality. Multidisciplinary, evidence-based guidelines for quality assurance in CRC screening and diagnosis have been developed by experts in a project co-financed by the European Union. The 450-page guidelines were published in book format by the European Commission in 2010.They include 10 chapters and over 250 recommendations, individually graded according to the strength of the recommendation and the supporting evidence. Adoption of the recommendations can improve and maintain the quality and effectiveness of an entire screening process, including identification and invitation of the target population, diagnosis and management of the disease and appropriate surveillance in people with detected lesions. To make the principles, recommendations and standards in the guidelines known to a wider professional and scientific community and to facilitate their use in the scientific literature, the original content is presented in journal format in an open-access Supplement of Endoscopy. The editors have prepared the present overview to inform readers of the comprehensive scope and content of the guidelines. IntroductionAccording to recent estimates by the International Agency for Research on Cancer [1], colorectal cancer (CRC) is the most common cancer in Europe with 432 000 new cases reported annually in men and women combined. It is the second most common cause of cancer deaths in Europe with 212 000 deaths reported in 2008.Worldwide, CRC ranks third in incidence and fourth in mortality with an estimated 1.2 million cases and 0.6 million deaths annually. In the 27 Member States of the European Union (EU), CRC ranks first in incidence and second in mortality, with approximately 334000 new cases and 149000 deaths estimated in 2008.Even in those Member States in the lower range for age-standardized rates of CRC, the burden of disease is significantly greater when compared with many other HHS Public Access Author Manuscript Author ManuscriptAuthor ManuscriptAuthor Manuscript regions of the world (see reference [1]). CRC is therefore an important health problem across the EU.Screening can be effective in cancer control in populations with a significant burden of CRC, provided the services are of high quality [2]. The aim of CRC screening is to lower the burden of cancer in the population by discovering disease in its early, latent stages [3]. Evidence-based methods permit treatment that is more effective than if disease is diagnosed later when symptoms have occurred. Early treatment of invasive lesions, for example by endoscopic resection of early CRC, can also be less detrimental for quality of life. The endoscopic removal of pre-malignant lesions also reduces the incidence of CRC by avoiding the progression to cancer. Randomized trials in people of average risk invite...

show abstract

mentioning

confidence: 59%

Section: Author Manuscript Author Manuscriptmentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

European guidelines for quality assurance in colorectal cancer screening and diagnosis: Overview and introduction to the full Supplement publication

Karsa¹,

Patnick²,

Segnan³

et al. 2012

Endoscopy

249

187

View full text Add to dashboard Cite

show abstract

Impact of colorectal cancer screening on cancer-specific mortality in Europe: A systematic review

Gini

Zielonke

Meester

et al. 2020

European Journal of Cancer

123

View full text Add to dashboard Cite

Background: Populations differ with respect to their cancer risk and screening preferences, which may influence the performance of colorectal cancer (CRC) screening programs. This review aims to systematically compare the mortality effect of CRC screening across European regions. Methods: Six databases including Embase, Medline, Web of Science, PubMed publisher, Google Scholar and Cochrane Library were searched for relevant studies published before March 2018. Bibliographic searches were conducted to select studies assessing the effect of various screening tests (guaiac fecal occult blood test [gFOBT]; flexible sigmoidoscopy [FS]; fecal immunochemical test [FIT] and colonoscopy) on CRC mortality in Europe (PROSPERO protocol: CRD42016042433). Abstract reviewing, data extraction and risk of bias assessment were conducted independently by two reviewers. Results: A total of 18 studies were included; of which, 11 were related to gFOBT, 4 to FS, 2 to FIT and 1 to colonoscopy; 8 were randomised clinical trials, and 10, observational studies, and an approximately equal number of studies represented Northern, Western and Southern European regions. Among individuals invited to screening, CRC mortality reductions varied from 8% to 16% for gFOBT and from 21% to 30% for FS. When studies with a high risk of bias were considered, ranges were more extensive. The estimated effectiveness of gFOBT and FS screening appeared similar across different European regions.

show abstract

Faecal haemoglobin concentration predicts all-cause mortality

Deding¹,

Kaalby²,

Steele³

et al. 2023

European Journal of Cancer

View full text Add to dashboard Cite

European guidelines for quality assurance in colorectal cancer screening and diagnosis. First Edition – Organisation

Cited by 27 publications

References 110 publications

European guidelines for quality assurance in colorectal cancer screening and diagnosis: Overview and introduction to the full Supplement publication

European guidelines for quality assurance in colorectal cancer screening and diagnosis: Overview and introduction to the full Supplement publication

Impact of colorectal cancer screening on cancer-specific mortality in Europe: A systematic review

Faecal haemoglobin concentration predicts all-cause mortality

Contact Info

Product

Resources

About